15 patents
Utility
Heteroaryl and Heterocyclyl Compounds
28 Sep 23
Described herein are compounds of Formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof, related compositions and preparations thereof, as well as methods of making and using the same.
Richard Heidebrecht, Christopher P. Hencken, Omar De Paolis, Weiheng Wang, Matthew Buchanan
Filed: 4 Aug 21
Utility
Genetically Modified Cell Lines Expressing an Exogenous Substance and Uses Thereof
14 Sep 23
Described herein are genetically modified cells derived from a human cell and which contain at least one exogenous transcription unit inserted into at least one of five genomic insertion sites located in Chromosomes 1, 2, 7 and X, as well as compositions, pharmaceutical preparations, and implantable devices comprising the genetically modified cells, and methods of using the same for preventing or treating a disease, disorder, or condition.
Marissa R. Donovan, Elina Makino, Erika Pearson
Filed: 28 Jul 21
Utility
Compositions, Devices and Methods for Inducing Immune Responses to Infectious Agents
27 Jul 23
Described herein are implantable devices comprising cells engineered to express and secrete antigens of infectious agents.
Hozefa Bandukwala, David E. Moller, David Peritt
Filed: 4 May 21
Utility
Compositions, Devices, and Methods for Factor VII Therapy
20 Apr 23
Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
Filed: 27 Mar 20
Utility
Monoclonal Cell Lines Expressing an Exogenous Substance and Uses Thereof
9 Feb 23
Described herein are genetically modified cells derived from a human cell and which contain at least one exogenous transcription unit inserted into at least one of four open chromatin regions (OCRs) located on Chromosomes 2, 5, 8 and 12, as well as compositions, pharmaceutical preparations, and implantable devices comprising the genetically modified cells, and methods of using the same for preventing or treating a disease, disorder, or condition.
Lauren Emily Barney, Guillaume Carmona, Marianthi Papakosta, Jared A. Sewell
Filed: 20 Nov 20
Utility
Compounds, Polymers, Devices, and Uses Thereof
9 Feb 23
Described herein are compounds of Formula (I), polymers and implantable elements comprising compounds of Formula (II), and compositions and methods of use thereof.
Elyse Bourque, Richard Heidebrecht, Christopher P. Hencken
Filed: 11 Dec 20
Utility
Apparatuses and Methods for Formation of Particles
12 Jan 23
Described herein are apparatuses and methods for conditioning particles.
Michael Beauregard, Faith C. David-Hegerich, John Patrick Golden, Joseph Gordon, Erika Ellen Johnston, Robert James Miller, Justin David Morse, Peter Calvin Costello
Filed: 4 Dec 20
Utility
Methods of Evaluating Small Molecule-modified Polymers In Compositions
5 Jan 23
Described herein are methods for evaluating polymer compositions comprising polymers modified with a small molecule compound (e.g., afibrotic compound), including methods for determining the concentration levels of said compounds.
Richard Heidebrecht, Zoe Yin
Filed: 25 Sep 20
Utility
Methods of Evaluating Polypeptide-modified Polymers In Compositions
3 Nov 22
Described herein are methods for evaluating polymer compositions comprising polymers modified with a polypeptide (e.g., a cell-binding polypeptide), including methods for determining polypeptide concentration.
Richard Heidebrecht, Zoe Yin
Filed: 25 Sep 20
Utility
Compositions, Devices, and Methods for Treating Fabry Disease
25 Aug 22
Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.
Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
Filed: 27 Mar 20
Utility
Implantable Devices for Cell Therapy and Related Methods
6 Jan 22
Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same.
Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
Filed: 27 Sep 19
Utility
Implantable Particles and Related Methods
20 May 21
Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same.
Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
Filed: 27 Mar 19
Utility
Methods, Compositions, and Implantable Elements Comprising Stem Cells
20 May 21
Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same.
Devyn McKinley Smith, David Peritt, Omid Veiseh, Richard Heidebrecht, Robert James Miller
Filed: 27 Mar 19
Utility
Afibrotic Compounds, Devices, and Uses Thereof
4 Mar 21
Richard Heidebrecht, Robert James Miller, Omid Veiseh
Filed: 1 Mar 19
Utility
Biocompatible Hydrogel Capsules and Process for Preparing Same
6 Jan 21
Described herein are compositions and methods for preparing hydrogel capsules using a cross-linking solution comprising a process additive.
Lauren Emily Barney, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller
Filed: 28 Feb 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first